ATLANTA — The investigational ultra long-acting injectable GLP-1 receptor agonist (RA) MET-097 produced up to 14% weight loss, with the potential for improved tolerability compared with other GLP-1 ...
NEW YORK--(BUSINESS WIRE)--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced positive data ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback